IFF_HS_Our-Products_HOWARU_Signature-Strains_Strains_La-14

HOWARU® La-14®

HOWARU® La-14®

Lactobacillus acidophilus La-14®

Image credits: © IFF, Finland, 2021 (FESEM imaging VTT)

HOWARU® Lactobacillus acidophilus La-14® is a lactic acid bacterium of human origin that has been documented in over 115 scientific studies, including more than 35 clinical trial publications.

Product Information:
  • ~ 59 preclinical publications
  • 35+ clinical publications

Health Benefits:
Immune-HealthImmuneWomens-HealthWomen's

La-14® BLENDS

Learn more about IFF Health Sciences’ La-14® blends.

IFF_HS_Our-Products_HOWARU-Feminine-Health_1_Edit_final

HOWARU® Feminine Health

IFF_HS_Our-Products_HOWARU-Prenatal-Plus_2_cropped

HOWARU® Protect Prenatal +

La-14® CLINICAL STUDIES & PUBLICATIONS

Preclinical studies have shown La-14® can impact both the innate and the adaptive immune system.¹ These effects and antipathogenic activity are thought to be potential mechanisms behind the efficacy of La-14® combined with HN001™ for intimate health (HOWARU® Protect Prenatal+ and HOWARU® Feminine Health) as well as women’s health.² ³

In addition, these two strains together have been shown to support healthy vaginal colonization and microbiota through oral supplementation.⁴

DSC09513

Health Benefit Areas

Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.

Click on a Health Benefit to see more studies and learn more.

Supporting Daily Dose: 6B CFU HN001™, 9B CFU La-14®

Study Reference:

* Regional restrictions apply, please connect with your account manager for further information.

LEARN MORE

References: 1. Elawadli I et al.;Beneficial Microbes. 2014; 2. Bertuccini L et al.; Intl J Immunopathology Pharmacology. 2017; 3. Jang SE et al.;Nutrients. 2017; 4. De Alberti D et al.. Arch Gynecol Obstet. 2015